- Home
- OABI vs NEN Comparison
OABI vs NEN Comparison
Compare OABI & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- NEN
- Stock Information
- Founded
- OABI 2012
- NEN 1977
- Country
- OABI United States
- NEN United States
- Employees
- OABI N/A
- NEN N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- NEN Building operators
- Sector
- OABI Health Care
- NEN Real Estate
- Exchange
- OABI Nasdaq
- NEN Nasdaq
- Market Cap
- OABI 250.8M
- NEN 262.4M
- IPO Year
- OABI N/A
- NEN N/A
- Fundamental
- Price
- OABI $2.06
- NEN $73.75
- Analyst Decision
- OABI Strong Buy
- NEN
- Analyst Count
- OABI 3
- NEN 0
- Target Price
- OABI $7.00
- NEN N/A
- AVG Volume (30 Days)
- OABI 545.9K
- NEN 378.0
- Earning Date
- OABI 08-06-2025
- NEN 01-01-0001
- Dividend Yield
- OABI N/A
- NEN 6.57%
- EPS Growth
- OABI N/A
- NEN 58.97
- EPS
- OABI N/A
- NEN 4.56
- Revenue
- OABI $26,744,000.00
- NEN $82,531,485.00
- Revenue This Year
- OABI N/A
- NEN N/A
- Revenue Next Year
- OABI $45.02
- NEN N/A
- P/E Ratio
- OABI N/A
- NEN $16.17
- Revenue Growth
- OABI 27.07
- NEN 6.12
- 52 Week Low
- OABI $1.22
- NEN $68.98
- 52 Week High
- OABI $4.95
- NEN $84.00
- Technical
- Relative Strength Index (RSI)
- OABI 59.11
- NEN 50.87
- Support Level
- OABI $1.90
- NEN $73.02
- Resistance Level
- OABI $2.19
- NEN $73.44
- Average True Range (ATR)
- OABI 0.13
- NEN 0.14
- MACD
- OABI -0.00
- NEN 0.13
- Stochastic Oscillator
- OABI 40.51
- NEN 75.00
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.